Introduction {#s1}
============

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterised by hamartomas in multiple organs, with the brain being the most commonly affected organ ([@B1], [@B2]). Subependymal giant cell astrocytoma (SEGA) occurs at the foramen of Monro, with a reported lifetime prevalence between 5 and 24% ([@B3], [@B4]). Although SEGAs are generally benign and non-infiltrative, these may grow, and obstruct cerebrospinal fluid (CSF) flow, thereby increasing intracranial pressure. Typical symptoms of growing SEGA include headaches, blurred vision, nausea, vomiting, worsening of seizure control or new-onset seizures, and sudden death from acute hydrocephalus ([@B3], [@B5]).

Diagnosis of SEGA has changed from pathology-based to imaging-based ([@B6], [@B7]), but formal diagnostic criteria have only been available since 2012, when an expert panel at the International Tuberous Sclerosis Complex Consensus Conference defined SEGA as a lesion at the caudothalamic groove with a size of \>1 cm in any direction or a subependymal lesion at any location which has shown serial growth on consecutive imaging regardless of size ([@B7]). All SEGA-related studies performed before 2012 have been based on variable criteria, thus limiting the value of comparison ([@B8]).

Onset and growth of SEGA has been reported most commonly in the first two decades of life ([@B9]). In two of the largest series of operated SEGAs, the mean age of surgical intervention was 9.7 years ([@B10]), and 11.6 years, ([@B11]) suggesting that growth is most common at this age. SEGA have been reported in neonates ([@B9]). Data on SEGA prevalence and growth in adults are scarce. A retrospective case series of 16 patients with TSC who required SEGA surgery, highlighted that SEGA can still become symptomatic later in life ([@B12]).

Present guidelines recommend that patients with asymptomatic SEGA diagnosed during childhood should continue to be imaged periodically as adults to ensure that there is no growth ([@B13]). Patients with large or growing SEGA or with SEGA causing ventricular enlargement that are still asymptomatic, should undergo MRI (magnetic resonance imaging) scans more frequently, and such patients and their families should be educated regarding the symptoms of raised intracranial pressure ([@B7]).

Surgical resection (occasionally VP shunt alone) is the recommended intervention for acutely symptomatic individuals, while either surgical resection or medical therapy with mammalian/mechanistic target of rapamycin (mTOR) inhibitors can be effective for individuals with growing asymptomatic SEGA ([@B13]). Treatment decisions should be based on multiple factors such as the patient\'s clinical condition, anatomic considerations specific to SEGA, surgeon\'s experience, experience of the centre regarding use of mTOR inhibitors, prior history of SEGA resection, other TSC-related comorbidities, and patient/parental preference ([@B7]).

This is the first study evaluating prevalence, growth, symptoms, and treatment patterns in a large prospective cohort of adults with TSC-associated SEGA.

Methods {#s2}
=======

TOSCA, a large-scale non-interventional study in patients with TSC, was conducted at 170 sites in 31 countries. The study design and methodology of TOSCA has been published previously ([@B14]). The study enrolled patients of any age with TSC between August 2012 and November 2014 and followed for up to 5 years. Patient data, including demographics, and information related to clinical features of TSC across all organ systems, comorbidities and rare manifestations, were collected at baseline and at regular visits scheduled at a maximum interval of 1 year.

In this study, designed prior to the 2012 imaging-based consensus, prevalence, and growth of SEGA were defined as per clinical practice of the participating centres. We evaluated SEGA manifestations among adult patients (\>18 years) enrolled into the TOSCA study. SEGA-related questions included in the case report form (CRF) were presence of single or multiple SEGA, newly diagnosed SEGA, SEGA growth, clinical signs, and symptoms associated with SEGA and information regarding SEGA treatment. In addition, possible associations of SEGA prevalence with genotype were analysed using a Chi-square test. Statistical significance was set at *p*-value \< 0.05.

Statistics were descriptive considering the exploratory nature of this study. Categorical data were reported as frequencies and percentages, and continuous variables were expressed as mean (± standard deviation) or as median (range), unless stated otherwise.

The study was designed and conducted in accordance with the Good Clinical Practice principles, the Declaration of Helsinki and all local regulations. The institutional review board or ethics committee at each participating site approved required TOSCA-related documents. Written informed consent was obtained from all patients, parents or guardians before enrolment.

Results {#s3}
=======

A total of 2,214 patients with TSC were enrolled in TOSCA study, and data were analysed for 2,211 patients. In the final analysis performed on data collected until August 2017, a history of SEGA was reported in 30.3% (671/2,211; 332 males and 339 females) of patients. Other neuroimaging features reported included cerebral white matter radial migration lines in 25.5, cortical tubers in 87.2, and subependymal nodules 82.9%.

Of the 803 adult patients included in the final analysis, a history of SEGA was reported in 220 patients (27.4%). The demographic of the adult patients with SEGA are shown in [Table 1](#T1){ref-type="table"}. SEGA were ongoing during study in 186 (84.5%) patients. Of these, multiple and bilateral SEGA were reported in 66 (35.5%), and 61 (32.8%) patients, respectively. SEGA growth since previous scan was reported in 39 (21%). The median age at SEGA diagnosis in this adult cohort was 20 years (range, \<1--57 years), as compared to 7 years (range, \<1--57 years) in the entire TOSCA cohort.

###### 

Demographics of adult patients with SEGA.

  **Characteristics**                                                **Patients with SEGA**                                   
  ------------------------------------------------------------------ ------------------------ --------------- --------------- ----------------
  Age at diagnosis of TSC, years; median (range)                     4.0 (\<1--48)            1.0 (\<1--24)   4.0 (\<1--37)   15.0 (\<1--48)
  **Gender**, ***n*** **(%)**                                                                                                 
      Male                                                           98 (44.5)                35 (38.5)       46 (47.9)       17 (51.5)
      Female                                                         122 (55.5)               56 (61.5)       50 (52.1)       16 (48.5)
  Patients with molecular testing, *n* (%)                           96 (43.6)                40 (44.0)       41 (42.7)       15 (45.5)
  **Genetic Testing**, ***n*** **(%)**                                                                                        
      No mutation identified                                         12 (12.5)                6 (15.0)        3 (7.3)         3 (20.0)
      *TSC1* mutation                                                12 (12.5)                2 (5.0)         5 (12.2)        5 (33.3)
      *TSC2* mutation                                                69 (71.9)                31 (77.5)       31 (75.6)       7 (46.7)
      Results not available[^\*^](#TN1){ref-type="table-fn"}         5 (5.2)                  1 (2.5)         1 (2.4)         0
  **Variation Type**, ***n*** **(%)**                                                                                         
      Pathogenic mutation                                            59 (61.5)                22 (55.0)       27 (65.9)       10 (66.7)
      Variant of unknown significance                                5 (5.2)                  4 (10.0)        1 (2.4)         0
      Both pathogenic mutation and variant of unknown significance   2 (2.1)                  0               2 (4.9)         0
      Results not available[^\*^](#TN1){ref-type="table-fn"}         30 (31.3)                14 (35)         11 (26.8)       5 (33.3)
  Patients with prenatal diagnosis, *n* (%)                          1 (0.5)                  1 (1.1)         0               0

*Values are expressed as n (%), unless otherwise specified*.

*Include missing data and those results not made available due to legal/medical confidentiality statements*.

*SEGA, subependymal giant cell astrocytoma. TSC, tuberous sclerosis complex*.

The median interval between consecutive scans was 1 year (range \<1--34 years). During the study period (up to 5 years), 14 new diagnoses of SEGA were made (2.4% of total adults minus those with history of SEGA). The oldest patient with a newly reported SEGA was 57 years. Of the 186 adults with ongoing SEGA, 153 (82.3%) remained asymptomatic, and 33 (17.7%) were reported to ever have developed symptoms related to SEGA growth in the past, including primarily increase in seizure frequency (15.6%), behavioural disturbance (13.4%), and headache (10.8%), either alone or in combination with other symptoms ([Table 2](#T2){ref-type="table"}). Over time, SEGA had been treated with surgery in 55 out of 117 patients (47.0%) and with mTOR-inhibitors in 46 out of 117 patients (39.3%). Nine patients (7.7%) required a shunt for the management of hydrocephalus.

###### 

Clinical characteristics of SEGA.

                                                                                                           **Overall TOSCA population (*n* = 2211)**   **Adult patients**                           
  -------------------------------------------------------------------------------------------------------- ------------------------------------------- -------------------- ----------- ----------- -----------
  Patients with history of SEGA                                                                            671 (30.3)                                  220 (27.4)           91 (38.7)   96 (27.9)   33 (14.7)
  No. of patients with ongoing SEGA during the study, *n*                                                  579                                         186                  71          87          28
      Multiple                                                                                             240 (41.5)                                  66 (35.5)            24 (33.8)   33 (37.9)   9 (32.1)
      Bilateral                                                                                            236 (40.8)                                  61 (32.8)            21 (29.6)   30 (34.5)   10 (35.7)
      Growing SEGA since previous scan[^\*^](#TN2){ref-type="table-fn"}[^\#^](#TN3){ref-type="table-fn"}   208 (35.9)                                  39 (21.0)            19 (26.8)   17 (19.5)   3 (10.7)
  **Signs and symptoms**                                                                                                                                                                            
      None                                                                                                 476 (82.2)                                  153 (82.3)           57 (80.3)   72 (82.8)   24 (85.7)
      Increase in seizure frequency                                                                        98 (16.9)                                   29 (15.6)            14 (19.7)   13 (14.9)   2 (7.1)
      Behavioural disturbance                                                                              77 (13.3)                                   25 (13.4)            8 (11.3)    16 (18.4)   1 (3.6)
      Regression/loss of cognitive skills                                                                  51 (8.8)                                    16 (8.6)             5 (7.0)     10 (11.5)   1 (3.6)
      Headache                                                                                             47 (8.1)                                    20 (10.8)            7 (9.9)     10 (11.5)   3 (10.7)
      Ventriculomegaly                                                                                     32 (5.5)                                    8 (4.3)              5 (7.0)     3 (3.4)     0
      Increased intracranial pressure                                                                      24 (4.1)                                    10 (5.4)             6 (8.5)     2 (2.3)     2 (7.1)
      Sleep disorder                                                                                       22 (3.8)                                    7 (3.8)              1 (1.4)     6 (6.9)     0
      Eye movement abnormalities                                                                           16 (2.8)                                    6 (3.2)              4 (5.6)     2 (2.3)     0
      Visual impairment                                                                                    10 (1.7)                                    4 (2.2)              3 (4.2)     1 (1.1)     0
      Papilloedema                                                                                         8 (1.4)                                     4 (2.2)              2 (2.8)     1 (1.1)     1 (3.6)
      Neuroendocrine dysfunction                                                                           8 (1.4)                                     4 (2.2)              0           3 (3.4)     1 (3.6)
      Other                                                                                                28 (4.8)                                    7 (3.8)              4 (5.6)     3 (3.4)     0

*Values are expressed as n (%), unless otherwise specified*.

*Median time from previous scan to last assessment was 1 year*.

*Growing of SEGA since previous scan was measured among those with ongoing SEGA during the study. SEGA, subependymal giant cell astrocytoma*.

SEGA were significantly more frequent in adults with a *TSC2* mutation compared to those with a *TSC1* mutation (35.2 vs. 15.6%, *p* \< 0.0004). However, there was no significant difference in multiple (*p* = 0.1158), bilateral (*p* = 0.1062), or growing SEGA (*p* = 1.0000), and presence of SEGA-related symptoms (*p* = 0.2598) between those with *TSC1* and *TSC2* mutation. The median age at SEGA diagnosis was higher in patients with *TSC1* mutations (29 years, range 9--51) compared to patients with *TSC2* mutations (21 years, range \<1--49), but this difference was non-significant ([Table 3)](#T3){ref-type="table"}. Furthermore, 12 of 14 adults with newly diagnosed SEGA had mutations in *TSC2* gene, while two had no mutation identified.

###### 

Clinical characteristics of SEGA in adults with mutations in *TSC1* vs. *TSC2*.

                                                       **Adults with *TSC1* mutation (*n* = 77)**   **Adults with *TSC2* mutation (*n* = 196)**   ***p*-value**
  ---------------------------------------------------- -------------------------------------------- --------------------------------------------- ---------------
  Patients with history of SEGA                        12 (15.6)                                    69 (35.2)                                     0.0004
  Median (range) age at SEGA diagnosis, years          29 (9--51)                                   21 (\<1--49)                                  0.0599
  No. of patients with ongoing SEGA during the study   8 (66.7)                                     61 (88.4)                                     0.1317
      Multiple                                         5 (62.5)                                     19 (31.1)                                     0.1158
      Bilateral                                        5 (62.5)                                     18 (29.5)                                     0.1062
      Growing SEGA since previous scan                 1 (12.5)                                     13 (21.3)                                     1.0000
  **Signs and Symptoms**                                                                                                                          
      None                                             5 (62.5)                                     49 (87.5)                                     0.3580
      Increase in seizure frequency                    3 (37.5)                                     15 (28.3)                                     0.6243
      Behavioural disturbance                          1 (12.5)                                     14 (26.4)                                     1.0000
      Headache                                         1 (12.5)                                     10 (18.9)                                     0.5753
      Regression/loss of cognitive skills              0                                            5 (9.4)                                       1.0000
      Ventriculomegaly                                 0                                            4 (7.5)                                       1.0000
      Increased intracranial pressure                  1 (12.5)                                     3 (5.7)                                       1.0000
      Papilloedema                                     1 (12.5)                                     3 (5.7)                                       1.0000
      Sleep disorder                                   0                                            2 (3.8)                                       1.0000
      Eye movement abnormalities                       0                                            2 (3.8)                                       1.0000
      Visual impairment                                0                                            2 (3.8)                                       1.0000
      Neuroendocrine dysfunction                       1 (12.5)                                     2 (3.8)                                       0.2408
      Other                                            1 (12.5)                                     3 (5.7)                                       0.3098
  Patients received treatment                          8 (66.7)                                     37 (53.6)                                     0.0716

*Values are expressed as n (%), unless otherwise specified*.

*SEGA, subependymal giant cell astrocytoma*.

Discussion {#s4}
==========

To our knowledge, this is the first study to evaluate SEGA prevalence, growth, symptoms, and current treatment modalities in adults with TSC-associated SEGA. The international TOSCA study allowed us to evaluate data from 803 adults (age \> 18 years), 220 of whom had SEGA (27.4%). During the 5 years follow-up period of the study, 23.2% of adults reported that the SEGA was still ongoing.

The occurrence of new SEGA after the age of 18 years was relatively low (2.4%) but more common than previously thought ([@B7]). In this cohort, age at SEGA diagnosis was as late as 57 years. Newly diagnosed SEGA were associated with mutations in *TSC2* in the large majority of cases (85.7%). Other risk factors such as contrast enhancement of SEN in the caudo-thalamic groove were beyond the scope of this study.

Another key finding was that SEGA growth since previous scan (mean time of 1.5--2.3 years between previous scan and last assessment) was observed in 21% of our adult patients. Although not negligible, this is less frequent compared with children. In a cohort of 58 patients (33 children, 25 adults), Tsai et al. reported similar results, with SEGA growth in children being significantly higher than in adults (75.6 vs. 16.5%) ([@B15]).

The fact that SEGA may still grow during adulthood emphasises the need for continuous surveillance even after the age of 25 years. This was highlighted in the current guidelines that recommend that patients with asymptomatic SEGA diagnosed in childhood should continue to undergo periodical imaging as adults to ensure that there is no growth. This highlights the need for continued multidisciplinary follow-up, also at adult age. Although newly occurring SEGA during adulthood seem relatively rare and do not warrant systematic screening, physicians should keep this possibility in mind when symptoms potentially related to SEGA growth occur. Special attention should be paid to adults with mutations in *TSC2* since they seem to be at a higher risk for newly occurring SEGA and SEGA growth in adulthood as well as to individuals with intellectual disability who might not be able to verbally express SEGA-related symptoms. Importantly, certain SEGA-related symptoms (especially early symptoms) are not limited to signs of increased intracranial pressure, and therefore, parents and patients should be informed about all relevant symptoms which require referral for medical evaluation, particularly sudden behavioural changes such as acute-onset and unexplained aggression, academic difficulties or any other acute and unexplained manifestations of TSC-associated neuropsychiatric disorders (TAND) ([@B16]--[@B18]).

We acknowledge the limitations intrinsic to a large-scale, international, non-interventional/observational study. These included the fact that participants were recruited from expert TSC centres around the world and the fact that data on SEGA diagnosis, growth and SEGA-related symptoms were collected as reported per clinical practice. However, these limitations are, at least in part, offset by the large-scale and "real-world" nature of the cohort across multiple centres and countries. Being an observational study, detailed information on the treatment initiated for SEGA at adult age were not collected. The very low number of missing data for SEGA reflects good quality of data collection for this specific manifestation.

Conclusion {#s5}
==========

Findings from this large international study highlight the need for continued monitoring for SEGA growth in adults with ongoing SEGA. Clinicians and adults with TSC should be aware of the potential new onset SEGA in adults with SEGA-related symptoms, especially in the presence of mutations in *TSC2*.
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